kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
1,305
JPY
-5
(-0.38%)
Dec 5, 12:52 pm JST
8.41
USD
Dec 4, 10:52 pm EST
Result
PTS
outside of trading hours
1,307.9
Dec 5, 11:12 am JST
Summary Chart Historical News Financial Result
PER
16.7
PBR
0.74
Yield
3.07%
Margin Trading Ratio
57.10
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
1,308 JPY 8.43 USD
Previous Close Dec 4
1,310 JPY 8.43 USD
High Dec 5, 9:46 am
1,312 JPY 8.45 USD
Low Dec 5, 10:05 am
1,304 JPY 8.41 USD
Volume
17,500
Trading Value
0.02B JPY 0.15M USD
VWAP
1307.01 JPY 8.42 USD
Minimum Trading Value
130,500 JPY 841 USD
Market Cap
0.04T JPY 0.25B USD
Number of Trades
79
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
223
1-Year High Jul 14, 2025
1,532
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 33,900 37,000 1.09
Nov 21, 2025 35,300 38,800 1.10
Nov 14, 2025 23,500 40,400 1.72
Nov 7, 2025 22,700 45,100 1.99
Oct 31, 2025 23,000 43,600 1.90
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.